

Other indications for Tofacitinib

Adults:

→ *Rheumatoid Arthritis:*

Oral: 5 mg twice daily (as conventional tablets) or 11 mg once daily (as extended-release tablets). May switch from dosage of 5 mg twice daily (as conventional tablets) to dosage of 11 mg once daily (as extended-release tablets) the day following the last dose of the conventional tablets.

→ *Psoriatic Arthritis:*

Oral: 5 mg twice daily (as conventional tablets) or 11 mg once daily (as extended-release tablets). May switch from dosage of 5 mg twice daily (as conventional tablets) to dosage of 11 mg once daily (as extended-release tablets) the day following the last dose of the conventional tablets.

→ *Ulcerative Colitis:*

Oral: Induction: 10 mg twice daily (as conventional tablets) or 22 mg once daily (as extended-release tablets) for at least 8 weeks, then evaluate patient and, depending on therapeutic response, begin maintenance therapy. If necessary, may administer 10 mg twice daily (as conventional tablets) or 22 mg once daily (as extended-release tablets) for maximum of 16 weeks. If adequate therapeutic benefit not achieved after 16 weeks at this dosage, discontinue dosage. *Maintenance:* Recommended dosage is 5 mg twice daily (as conventional tablets) or 11 mg once daily (as extended-release tablets). May consider 10 mg twice daily (as conventional tablets) or 22 mg once daily (as extended-release tablets) for patients with loss of response during maintenance therapy. ^[1]

[1] - Ashley, Caroline, and Aileen Dunleavy. 2018. The Renal Drug Handbook: The Ultimate Prescribing Guide for Renal Practitioners, 5th Edition. 5th ed. London, England: Routledge, https://www.medicinainterna.net.pe/sites/default/files/The_Renal_Drug_Handbook_The_Ultimate.pdf

